Recent advances in nanotherapeutics for multiple myeloma

Simple item page
dc.contributor.authorIannazzo, Daniela
dc.contributor.authorEttari, Roberta
dc.contributor.authorGiofrè, Salvatore Vincenzo
dc.contributor.authorEid, Ali H.
dc.contributor.authorBitto, Alessandra
dc.contributor.departmentPharmacology and Toxicology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:39:43Z
dc.date.available2025-01-24T11:39:43Z
dc.date.issued2020
dc.description.abstractAnticancer therapies cannot be included in a one-size-fits-all scenario; it is imperative to adapt therapies to the tumor molecular profile and most importantly to develop target-specific therapeutics. Nanotherapeutics can combine molecular imaging with molecular therapy in order to provide the maximum benefit to patients in terms of disease prevention, identification, and treatment. Nanotechnology applied to therapy provides numerous advantages in diagnostics and in drug delivery, especially for those malignant cells that are diffcult to target or for drugs with poor bioavailability, such as those used for multiple myeloma (MM). This review summarizes the recent advances in the development of nanoparticle-based systems for the treatment of MM, taking into account the methods used for their functionalization, biocompatibility, and anticancer activity. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.
dc.identifier.doihttps://doi.org/10.3390/cancers12113144
dc.identifier.eid2-s2.0-85094900259
dc.identifier.urihttp://hdl.handle.net/10938/29333
dc.language.isoen
dc.publisherMDPI AG
dc.relation.ispartofCancers
dc.sourceScopus
dc.subjectLiposome
dc.subjectMultiple myeloma
dc.subjectNanotechnology
dc.subjectNanotherapeutics
dc.subjectAntineoplastic agent
dc.subjectArsenic trioxide
dc.subjectAscorbic acid
dc.subjectBortezomib
dc.subjectCarbon nanotube
dc.subjectCarfilzomib
dc.subjectChitosan
dc.subjectDaratumumab
dc.subjectDexamethasone
dc.subjectDna vaccine
dc.subjectDoxorubicin
dc.subjectElotuzumab
dc.subjectFullerene derivative
dc.subjectGold nanoparticle
dc.subjectGraphene oxide
dc.subjectIxazomib
dc.subjectLenalidomide
dc.subjectMacrogol
dc.subjectMelphalan
dc.subjectMesoporous silica nanoparticle
dc.subjectNanomaterial
dc.subjectNanoparticle
dc.subjectPaclitaxel
dc.subjectPanobinostat
dc.subjectPolycarbonate
dc.subjectPolyethyleneimine
dc.subjectPolyglactin
dc.subjectPolyvinyl alcohol
dc.subjectPomalidomide
dc.subjectPorphyrin
dc.subjectQuantum dot
dc.subjectSingle walled nanotube
dc.subjectSnake venom
dc.subjectThalidomide
dc.subjectTitanium dioxide nanoparticle
dc.subjectUltrasmall superparamagnetic iron oxide
dc.subjectZinc oxide nanoparticle
dc.subjectAntineoplastic activity
dc.subjectBiocompatibility
dc.subjectBone marrow suppression
dc.subjectDrug accumulation
dc.subjectDrug bioavailability
dc.subjectDrug blood level
dc.subjectDrug clearance
dc.subjectDrug cytotoxicity
dc.subjectDrug delivery system
dc.subjectDrug efficacy
dc.subjectDrug formulation
dc.subjectDrug half life
dc.subjectDrug potentiation
dc.subjectDrug selectivity
dc.subjectDrug targeting
dc.subjectDrug tolerability
dc.subjectHuman
dc.subjectIc50
dc.subjectInternalization
dc.subjectMicelle
dc.subjectNanoencapsulation
dc.subjectNanomedicine
dc.subjectNonhuman
dc.subjectParticle size
dc.subjectPeripheral neuropathy
dc.subjectPhotodynamic therapy
dc.subjectPhotothermal therapy
dc.subjectReview
dc.subjectSustained drug release
dc.subjectVaccine immunogenicity
dc.titleRecent advances in nanotherapeutics for multiple myeloma
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2020-6458.pdf
Size:
2.11 MB
Format:
Adobe Portable Document Format
Download

Collections

Pharmacology and Toxicology